With Prostate-Specific Antigen (PSA) Screening Questioned, Why Not Hurl Out the Next Unproven Prostate Tests?

Tweet The headline in the New York Times story this morning, “New Prostate Cancer Tests Could Reduce False Alarms,” by Andrew Pollack, had me scratching my head. Had I missed something in the story of advances in prostate cancer screening and diagnosis? The search for finding something better than PSA tests to reduce false positives

Delay of Generics Hurts Consumer,
Taxpayer Wallets, and Patient Health

Tweet   To insure patent extensions of high-priced, blockbuster drugs, brand-name drug companies frequently pay generic drug manufacturers to stay out of the market. It makes cheaper, more affordable generic unavailable for years. The strategy is referred to as “Pay for Delay.” The Federal Trade Commission has lots of information on this problem and its

Meeting Time, Ethical Issues in Psychiatry

Tweet I am heading to the annual meeting of the Association of Healthcare Journalists, have been occupied with paying work for a change, and cannot do the usual detailed post I do here. In the meantime, it’s worth flagging some recent health news that patients might want to think about. Ethical Issues in Psychiatry Last week,

Mental health medication: is it always A Bad Thing?

Tweet THIS is a guest post written by Martha Roberts, a journalist and mental health blogger in the UK, who writes the blog, Mentalhealthwise. Martha is on twitter @martharoberts01. Thank you, Martha. ###### ‘So when can you come off your medication, now you’re feeling so much better?’, someone asked me recently. ‘Well…um, never,’ I replied.

Mental Health and the Patient Point of View:
More High-Quality Stories Needed

Tweet I am thrilled that later today, Martha Roberts’ post on her own experience taking medication for mental illness, will run here. I first came across her post through a tweet from Ben Goldacre, author of Bad Pharma. It’s nice to know that he has not oversimplified the “bad pharma” argument into this meme: all